🔎 Trials Near Me

Início › Câncer de Próstata › Illinois › Chicago

Ensaios clínicos de Câncer de Próstata em Chicago, IL

45 estudos para Câncer de Próstata estão buscando participantes em locais em Chicago e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.

Texto oficial do estudo (Inglês)

Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

RecrutandoFase 3
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
Idades 18 e acima · Homens · Atualizado em 2 de out. de 2026 · NCT06931340

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

RecrutandoFase 3
  • Northwestern University, Chicago
Idades 18 e acima · Homens · Atualizado em 2 de out. de 2026 · NCT07200830

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

RecrutandoFase 1
  • University of Chicago Hospital, Chicago
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • e mais 1
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

RecrutandoFase 2
  • University of Illinois Cancer Center, Chicago
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

RecrutandoFase 2
  • Rush MD Anderson Cancer Center, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT03866382

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

RecrutandoFase 3
  • University of Illinois Chicago, Chicago
Idades 18 e acima · Homens · Atualizado em 22 de set. de 2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

RecrutandoFase 3
  • Northwestern University, Chicago
  • University of Illinois Cancer Center at Chicago, Chicago
Idades de 18 a 100 · Homens · Atualizado em 22 de set. de 2026 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

RecrutandoFase 3
  • Research Site, Chicago
Idades 18 e acima · Homens · Atualizado em 18 de set. de 2026 · NCT06952803

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

RecrutandoFase 3
  • Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
  • University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
Idades 18 e acima · Homens · Atualizado em 17 de set. de 2026 · NCT06925737

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

RecrutandoFase 3
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • Advocate Illinois Masonic Medical Center, Chicago
Idades 18 e acima · Homens · Atualizado em 10 de set. de 2026 · NCT05946213

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

RecrutandoFase 1
  • University of Illinois Hospital & Health Sciences System, Chicago
Idades 18 e acima · Homens · Atualizado em 8 de set. de 2026 · NCT05800665

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Recrutando
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Idades 18 e acima · Homens · Atualizado em 1 de set. de 2026 · NCT05710380

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

RecrutandoFase 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Idades 18 e acima · Homens · Atualizado em 31 de ago. de 2026 · NCT05726292

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

RecrutandoFase 2
  • Jesse Brown VA Medical Center, Chicago, IL, Chicago
Idades 18 e acima · Homens · Atualizado em 25 de ago. de 2026 · NCT05593497

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

RecrutandoFase 1/2
  • University of Chicago, Chicago
Idades 18 e acima · Homens · Atualizado em 20 de ago. de 2026 · NCT06785636

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

RecrutandoFase 3
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
Idades 18 e acima · Homens · Atualizado em 19 de ago. de 2026 · NCT04423211

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

RecrutandoFase 1
  • University of Chicago Medical Center, Chicago
Idades de 18 a 100 · Homens · Atualizado em 13 de ago. de 2026 · NCT05519449

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

RecrutandoFase 1/2
  • Research Site, Chicago
Idades de 18 a 130 · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT05417594

PSMA PET Combined With MRI for the Detection of PCa

RecrutandoFase 3Voluntários saudáveis bem-vindos
  • UroPartners,LLC, Chicago
Idades 18 e acima · Homens · Atualizado em 23 de jul. de 2026 · NCT07052214

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

RecrutandoFase 3
  • University of Illinois, Chicago
Idades 18 e acima · Homens · Atualizado em 14 de jul. de 2026 · NCT06592924

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

RecrutandoFase 2
  • Northwestern University, Chicago
Idades 18 e acima · Homens · Atualizado em 14 de jul. de 2026 · NCT05691465

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

RecrutandoFase 1 inicialVoluntários saudáveis bem-vindos
  • Northwestern University, Chicago
Idades 18 e acima · Homens · Atualizado em 2 de jul. de 2026 · NCT05852041

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

RecrutandoFase 2
  • UChicago Medicine Comprehensive Cancer Center, Chicago
Idades 18 e acima · Homens · Atualizado em 16 de jun. de 2026 · NCT05790213

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

RecrutandoEstudo observacional
  • University of Illinois at Chicago, Chicago
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
  • University of Chicago, Chicago
Idades 21 e acima · Homens · Atualizado em 22 de mai. de 2026 · NCT03151629

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
  • Northwestern, Chicago
Idades 40 e acima · Homens · Atualizado em 15 de mai. de 2026 · NCT04472338

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

RecrutandoFase 1
  • Research Site, Chicago
Idades 18 e acima · Homens · Atualizado em 12 de mai. de 2026 · NCT06879041

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

RecrutandoFase 1/2
  • Rush University, Chicago
Idades 18 e acima · Homens · Atualizado em 5 de mai. de 2026 · NCT06616155

Clinical Trial of Approaches to Prostate Cancer Surgery

Recrutando
  • Northwestern University, Chicago
Idades de 40 a 80 · Homens · Atualizado em 22 de abr. de 2026 · NCT05155501

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

RecrutandoFase 2
  • Northwestern University, Chicago
Idades 18 e acima · Homens · Atualizado em 30 de mar. de 2026 · NCT06244004

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

RecrutandoFase 1/2
  • University of Chicago Medical Center, Chicago
Idades 18 e acima · Todos os sexos · Atualizado em 27 de mar. de 2026 · NCT06395519

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

Recrutando
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Idades 18 e acima · Homens · Atualizado em 4 de mar. de 2026 · NCT06171269

GU-01: Glycyrrhizin in Prostate Cancer

RecrutandoFase 2
  • University of Illinois, Chicago
Idades 18 e acima · Homens · Atualizado em 23 de fev. de 2026 · NCT06378346

PSMA PET for Surveillance After Focal Therapy

Recrutando
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Idades 18 e acima · Homens · Atualizado em 17 de fev. de 2026 · NCT07115914

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

RecrutandoFase 1
  • The University of Chicago Comprehensive Cancer Center, Chicago
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT06778863

Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)

RecrutandoEstudo observacional
  • The University of Chicago, Hyde Park · a 5 mi de distância
Idades 22 e acima · Homens · Atualizado em 2 de fev. de 2026 · NCT06705803

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

RecrutandoFase 4
  • University of Chicago Medical Center, Chicago
Idades de 18 a 64 · Todos os sexos · Atualizado em 22 de jan. de 2026 · NCT04373564

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecrutandoEstudo observacional
  • Massive Bio SYNERGY-AI site, Chicago
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Recrutando
  • The University of Illinois at Chicago (UIC), Chicago
  • UChicago Medicine Comprehensive Cancer Center, Chicago
Idades 70 e acima · Homens · Atualizado em 1 de out. de 2025 · NCT06824818

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

RecrutandoFase 3
  • Rush University Medical Center, Chicago
  • University of Illinois, Chicago
Idades 18 e acima · Homens · Atualizado em 11 de set. de 2025 · NCT03678025

Geriatric Assessment and Technology Evaluation in Prostate Cancer

RecrutandoEstudo observacional
  • o University of Chicago Medicine Comprehensive Cancer Center, Chicago
18 Minutes · Homens · Atualizado em 8 de jun. de 2025 · NCT06215508

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

RecrutandoFase 4
  • University of Chicago Medical Center, Chicago
Idades de 18 a 80 · Homens · Atualizado em 18 de out. de 2024 · NCT05629494

Ensaios de Câncer de Próstata em outras cidades

Outros estudos em Chicago

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.